NERANDOMILAST
Information current as at: 1 July 2026
PBAC meeting date: November 2026
Submission Details
- Brand name:
-
- Jascayd®
- Form and strength:
-
- Tablet 9 mg
- Tablet 18 mg
- Submission sponsor:
- BOEHRINGER INGELHEIM PTY LTD
- Condition/indication:
(therapeutic use) -
- Progressive pulmonary fibrosis (PPF)
- Listing requested:
- To request listing of nerandomilast for the treatment of patients with PPF who: - are treatment-naïve and initiate nerandomilast as their first pharmacological therapy; - have discontinued nintedanib due to intolerance, adverse events, or disease progression, and who subsequently receive nerandomilast as monotherapy; and - receive nerandomilast in combination with nintedanib.
- Funding program:
- PBS General Schedule
- Request authority level:
- Authority Required (Telephone/Online)
- PBAC Submission type:
- New PBS listing (–)
- Comment:
- --
- Other PBAC consideration:
- --
Progress Details
-
Submission received for: - November 2026 PBAC meeting
-
2Opportunity for consumer comment:
- Open 22/07/2026 and close 16/09/2026 (see PBS Website)
-
3PBAC meeting:
- Has not yet occurred
-
4PBAC outcome published:
- Pending PBAC outcome (see PBAC Outcomes)
-
5Lodgement of required documentation:
-
6Agreement to listing arrangements:
- Has not yet commenced
-
7Government processes:
- Has not yet commenced
-
8Medicine listed on the PBS:
- Has not yet occurred
PBAC Outcome
Case ID
a1295
Page last updated
23 July 2026
v.9.19